Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISTINCT: Dinutuximab + Irinotecan in SCLC
NCT03098030Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jun 2017
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of dinutuximab in small cell lung cancer (SCLC), sponsored by United Therapeutics Corporation. Started Jun 2017; status: completed.
02
Drugs
dinutuximab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03098030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03098030.